Economic Analysis of Catheter‐Directed Thrombolysis for Intermediate‐Risk Pulmonary Embolism
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Elina Pliakos und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pulmonary Embolism, Thrombolytic Therapy, Fibrinolytic Agents, Drug Costs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Background
Pulmonary embolism is associated with a significant burden of morbidity, mortality, and health care costs. Catheter‐directed thrombolysis has emerged as a promising option for patients with intermediate‐risk pulmonary embolism which aims to improve outcomes over standard anticoagulation.
Methods
We constructed a decision‐analytic model comparing the cost‐effectiveness of catheter‐directed thrombolysis to anticoagulation alone for the management of intermediate‐risk pulmonary embolism. Cost‐effectiveness was determined by calculating deaths averted and incremental cost‐effectiveness ratios (ICER). Uncertainty was addressed by plotting cost‐effectiveness planes and acceptability curves for various willingness‐to‐pay thresholds. The main outcome was ICER (US dollars/deaths averted).
Results
In the base case analysis, derived using systemic lysis data, the cost associated with catheter‐directed thrombolysis was estimated at $22,353 with a probability of survival at 1 month of 0.984. For the anticoagulation alone strategy, the cost was $25,060, and the probability of survival at 1 month was 0.958. Overall, catheter‐directed thrombolysis resulted in savings of $104,089 per death averted (ICER,—$104,089 per death averted). Sensitivity analysis revealed that catheter‐directed thrombolysis would no longer be cost‐effective when its associated mortality is greater than 0.042. In the probabilistic analysis, at a willingness‐to‐pay of $100,000, catheter‐directed thrombolysis had a 63% chance of being cost‐effective, and in cost‐effectiveness acceptability curves, it was cost‐effective in 63%–78% of simulations for a willingness to pay ranging from $0 to $100,000.
Conclusions
If the assumptions made in our model are shown to be accurate then CDT would be cost‐effective and may lead to considerable cost savings if used where clinically appropriate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Pulmonary Medicine, Allergy, and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Elina Pliakos, Taisei Kobayashi
Zitieren
APA
Pliakos, E., Glassmoyer, L., Kobayashi, T., Pugliese, S., Shankar, H., Matthai, W., Khandhar, S., Giri, J., & Nathan, A. (2025). Economic Analysis of Catheter‐Directed Thrombolysis for Intermediate‐Risk Pulmonary Embolism. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31280
Vancouver
Pliakos E, Glassmoyer L, Kobayashi T, Pugliese S, Shankar H, Matthai W, et al. Economic Analysis of Catheter‐Directed Thrombolysis for Intermediate‐Risk Pulmonary Embolism. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31280
BibTeX
@article{Pliakos2025,
author = {Pliakos, Elina and Glassmoyer, Lauren and Kobayashi, Taisei and Pugliese, Steven and Shankar, Hari and Matthai, William and Khandhar, Sameer and Giri, Jay and Nathan, Ashwin},
title = {Economic Analysis of Catheter‐Directed Thrombolysis for Intermediate‐Risk Pulmonary Embolism},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31280}
}
EUVIMED